TY  - CHAP
M1  - Book, Section
TI  - Gestational Trophoblastic Disease
A1  - Cun, Han T.
A1  - Shafer, Aaron
A2  - Kantarjian, Hagop M.
A2  - Wolff, Robert A.
A2  - Rieber, Alyssa G.
PY  - 2022
T2  - The MD Anderson Manual of Medical Oncology, 4e
AB  - KEY  CONCEPTSGestational  trophoblastic  disease  (GTD)  is  a  spectrum  of  rare  tumors  that  arise  from  abnormal  placental  trophoblastic  tissue,  including  benign  disease  such  as  complete  and  partial  hydatidiform  moles,  as  well  as  malignant  tumors  such  as  invasive  mole,  choriocarcinoma,  placental  site  trophoblastic  tumor,  and  epithelioid  trophoblastic  tumor.Risk  factors  for  GTD  include  geography,  socioeconomic  status,  dietary  factors,  maternal  age,  and  previous  GTD  history.GTD  is  historically  diagnosed  based  on  pathology,  but  due  to  earlier  detection  because  of  routine  early  ultrasonography,  diagnosis  of  a  molar  pregnancy  based  on  histology  alone  may  be  difficult,  and  cytogenetic  techniques  can  assist  in  diagnosis.The  diagnosis  of  malignant  disease,  or  gestational  trophoblastic  neoplasia,  is  based  on  increase  or  plateau  of  human  chorionic  gonadotropin  (hCG)  levels,  tissue  diagnosis  of  choriocarcinoma,  or  evidence  of  metastatic  disease.After  the  diagnosis  of  malignant  disease,  it  is  imperative  that  patients  be  staged  and  scored  using  International  Federation  of  Gynecology  and  Obstetrics  2000  staging  incorporating  the  modified  World  Health  Organization  scoring  system  to  determine  whether  single-  or  multiagent  therapy  is  appropriate.Throughout  the  course  of  treatment,  patients  should  be  monitored  with  every  1-  to  2-week  serum  hCG  levels  to  determine  response.  
SN  - 
PB  - McGraw Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - hemonc.mhmedical.com/content.aspx?aid=1190837449
ER  -